Ernst Geutjes, PhD, is a biotechnology entrepreneur, oncology executive and investment professional with deep expertise in cancer research, oncology drug development and venture creation. He currently serves as CEO of Genase Therapeutics and supports investors, entrepreneurs and biotechnology companies through Oncopreneur, his oncology focused interim-management and consultancy practice.

Throughout his career Ernst has worked on both sides of the table as entrepreneur and investor. As Venture Partner at Aglaia Oncology Funds, a venture capital firm specialized in oncology therapeutics, he evaluated more than 1,500 oncology investment opportunities and supported the development of multiple portfolio companies. His experience spans a broad range of technologies including small molecules, antibodies, ADCs, immunotherapies and platform technologies. 

Ernst has held executive and entrepreneurial roles across multiple biotechnology companies, including Genase Therapeutics, Neohla Bioscience, Inthera Bioscience, Flindr Therapeutics and Sapreme Technologies. He has contributed to company creation, fundraising strategy, intellectual property development and translational R&D programs. He was involved in multiple venture creation efforts and financing rounds, including Flindr Therapeutics' EUR 20 million Series A financing. 

Prior to his venture career, Ernst trained as a scientist at Harvard Medical School and the Netherlands Cancer Institute. His passion lies in translating breakthrough science into products and companies that can transform cancer treatment.